Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665730 | SCV000789896 | uncertain significance | Glycogen storage disease, type II | 2017-03-13 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000665730 | SCV005725914 | likely pathogenic | Glycogen storage disease, type II | 2024-11-01 | criteria provided, single submitter | clinical testing | Variant summary: GAA c.1280T>C (p.Met427Thr) results in a non-conservative amino acid change located in the Glycoside hydrolase family 31, TIM barrel domain (IPR000322) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 236646 control chromosomes. c.1280T>C has been reported in the presumed compound heterozygous state in the literature in multiple individuals affected with Glycogen Storage Disease, Type 2 (Pompe Disease) (example, Ding_2015, Li_2023, Zhao_2024). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported, however all individuals cited had residual/low GAA enzyme activity <30% of control values, which could not be entirely explained by the opposite allele (example, Ding_2015, Li_2023, Zhao_2024). The following publications have been ascertained in the context of this evaluation (PMID: 26310554, 38162137, 39010129). ClinVar contains an entry for this variant (Variation ID: 550859). Based on the evidence outlined above, the variant was classified as likely pathogenic. |